Same Dosages of rPRV/XJ5-gI-/gE-/TK- Prototype Vaccine or Bartha-K61 Vaccine Similarly Protects Growing Pigs Against Lethal Challenge of Emerging vPRV/XJ-5 Strain

Qinghai Ren; Lin Li; Haochun Pan; Xiaobo Wang; Qingqing Gao; Changchao Huan; Jin Wang; Wei Zhang; Luyao Jiang; Song Gao; Yan Kai; Changhai Chen

doi:10.3389/fvets.2022.896689

Same Dosages of rPRV/XJ5-gI^-/gE^-/TK^- Prototype Vaccine or Bartha-K61 Vaccine Similarly Protects Growing Pigs Against Lethal Challenge of Emerging vPRV/XJ-5 Strain

Front Vet Sci. 2022 Jul 1:9:896689. doi: 10.3389/fvets.2022.896689. eCollection 2022.

Authors

Qinghai Ren^{1

2

3

4}, Lin Li^{1

2

3

4}, Haochun Pan^{1

2

3

4}, Xiaobo Wang^{1

2

3

4}, Qingqing Gao^{1

2

3

4}, Changchao Huan^{1

2

3

4}, Jin Wang^{1

2

3

4}, Wei Zhang^{1

2

3

4}, Luyao Jiang^{1

2

3

4}, Song Gao^{1

2

3

4}, Yan Kai⁵, Changhai Chen⁵

Affiliations

¹ Key Laboratory of Avian Bioproducts Development, Ministry of Agriculture and Rural Affairs, Yangzhou University, Yangzhou, China.
² Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, China.
³ Institutes of Agricultural Science and Technology Development, Yangzhou University, Yangzhou, China.
⁴ College of Veterinary Medicine, Yangzhou University, Yangzhou, China.
⁵ Jiangsu Provincial Center for Animal Disease Control and Prevention, Nanjing, China.

Abstract

Variant pseudorabies viruses (vPRV) have constantly emerged in China since late 2011. In the present study, a 1 × 10^6.0 TCID₅₀ per-animal dosage of a commercially available Bartha-K61 vaccine and an rPRV/XJ5-gI^-/gE^-/TK^- prototype vaccine freshly extracted from the vPRV/XJ-5 at the same dose were administered to evaluate the immune effectiveness thereof on growing pigs to prevent lethal strikes caused by vPRV/XJ-5. The results suggest that the Bartha-K61 vaccine at a dose of 1 × 10^6.0 TCID₅₀ per animal and the same dosage of the rPRV/XJ5-gI^-/gE^-/TK^- prototype vaccine protected growing pigs against the lethal challenge of vPRV/XJ-5 strain with 100% survive rate. Furthermore, the outcome of the clinical score, virus shedding, weight gain, and viral loads in different pig tissues in these two groups demonstrates that either the Bartha-K61 vaccine or the rPRV/XJ5-gI^-/gE^-/TK^- prototype vaccine at the same dose exhibited parallel efficacy in pigs against the lethal challenge with the XJ-5 strain of vPRV.

Keywords: Bartha-K61 vaccine; efficacy; growing pigs; pseudorabies; rPRV/XJ5-gI−/gE−/TK− prototype vaccine; variant pseudorabies virus.